Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, People's Republic of China.
The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Cardiovasc Diabetol. 2022 May 14;21(1):74. doi: 10.1186/s12933-022-01516-6.
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
心血管疾病（CVDs）是 2 型糖尿病（T2DM）患者死亡的主要原因，尤其是在低收入和中等收入国家。为了有效预防 T2DM 患者发生 CVDs，人们一直在努力探索新的预防方法，包括个体化血糖控制和心血管风险管理（严格的血压和血脂控制），以及最近开发的降血糖药物和降脂药物。本综述主要针对考虑患者心血管状况时影响选择抗糖尿病药物和调脂、降压及抗血小板治疗的重要问题进行讨论。最后，我们还讨论了 T2DM 患者 CVD 治疗原则的变化。
